In 2017, generics accounted for 90% of prescriptions in the United States, and while brand name drugs accounted for just 10% of prescriptions, they were responsible for 77% of prescription spending.
As the nation grapples with ways to lower healthcare costs, access to generics plays a large role in saving patients, and the health system, money at the pharmacy counter. In 2017 alone, generics generated $265 billion in savings, according to a report from the Association for Accessible Medicines.
Savings for Medicare and Medicaid alone totaled $82.7 billion and $40.6 billion, respectively.
In 2017, generics accounted for 9 of every 10 prescriptions filled in the United States, and 93% of these prescriptions were filled at $20 or less. While brand name drugs accounted for just 10% of prescriptions, they were responsible for 77% of prescription spending. Due to high costs, those prescribed brand name drugs were 2 to 3 times more likely to not pick up their prescription after calling it in.
Looking by drug class, the biggest savings were seen in mental health, which saved $42 billion from generic drugs, followed by $34 billion for cholesterol and $31 billion for hypertension. By patient condition, savings totaled $48 billion for mental illness, $47 billion for heart disease, and $17 billion for epilepsy.
Savings by state averaged $5.2 billion, ranging from $354 million in Alaska to $23.2 billion in California.
In recent years, the gradual introduction of biosimilars to the market has provided another outlet for prescription cost savings. In the 8 years since the passage of the Biologics Price Competition and Innovation Act (BPCIA), 12 biosimilars have been approved, most recently a second biosimilar to Amgen’s reference filgrastim (Neupogen), used to treat neutropenia.
With biologics often coming with hefty price tags, “biosimilars have the potential to improve the quality of life for American patients while at the same time saving the health system billions of dollars each year—provided that the right policies are in place to nurture a robust marketplace,” states the report.
However, despite 12 FDA approvals, just 4 biosimilars have entered the US market, as others are tied up in pending litigation. Under the BPCIA, drug innovators are provided 12 years of market exclusivity to make up for research and development costs. And even when that 12-year period has ended, biosimilars still have hurdles to climb.
The report gave the example of adalimumab (Humira), used to treat rheumatoid arthritis and Crohn disease, which comes with a list price of $38,000. Despite its primary patent being expired, the 2 FDA-approved biosimilars to the drug are being blocked from entering the market through the patent process. In the meantime, the price of the reference Humira continues to rise, increasing 122% over the past 5 years.
To learn more about biosimilars, visit The Center for Biosimilars®, a sister site of The American Journal of Managed Care®.
Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks
April 30th 2024Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More